

Highlights of This Issue 325

SPECIAL FEATURES

CCR Translations

327 Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?

Alexandria P. Cogdill, Peter A. Prieto, Alexandre Reuben, and Jennifer A. Wargo
See related article, p. 351

CCR Drug Updates

330 U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Harpreet Singh, Michael Brave, Julia A. Beaver, Joyce Cheng, Shenghui Tang, Eias Zahalka, Todd R. Palmby, Rajesh Venugopal, Pengfei Song, Qi Liu, Chao Liu, Jingyu Yu, Xiao Hong Chen, Xing Wang, Yaning Wang, Paul G. Kluetz, Selena R. Daniels, Elektra J. Papadopoulos, Rajeshwari Sridhara, Amy E. McKee, Amna Ibrahim, Geoffrey Kim, and Richard Pazdur

Molecular Pathways

336 Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins

Akihide Yoshimi and Omar Abdel-Wahab

Review

342 Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Eric K. Ring, James M. Markert, G. Yancey Gillespie, and Gregory K. Friedman

CANCER THERAPY: CLINICAL

351 A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma

Drew C. Deniger, Mei Li M. Kwong, Anna Pasetto, Mark E. Dudley, John R. Wunderlich, Michelle M. Langhan, Chyi-Chia Richard Lee, and Steven A. Rosenberg

See related commentary, p. 327

363 Branched Chain RNA *In Situ* Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer

Philip J. Saylor, Richard J. Lee, Kshitij S. Arora, Vikram Deshpande, Rong Hu, Kara Olivier, Erika Meneely, Miguel N. Rivera, David T. Ting, Chin-Lee Wu, and David T. Miyamoto

PERSONALIZED MEDICINE AND IMAGING

370 Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

Kurt A. Schalper, Daniel Carvajal-Hausdorf, Joseph McLaughlin, Mehmet Altan, Vamsidhar Velcheti, Patricia Gaule, Miguel F. Sanmamed, Lieping Chen, Roy S. Herbst, and David L. Rimm

379 Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer

Heather A. Parsons, Julia A. Beaver, Ashley Cimino-Mathews, Siraj M. Ali, Jennifer Axilbund, David Chu, Roisin M. Connolly, Rory L. Cochran, Sarah Croessmann, Travis A. Clark, Christopher D. Gocke, Stacie C. Jeter, Mark R. Kennedy, Josh Lauring, Justin Lee, Doron Lipson, Vincent A. Miller, Geoff A. Otto, Gary L. Rosner, Jeffrey S. Ross, Shannon Slater, Philip J. Stephens, Dustin A. VanDenBerg, Antonio C. Wolff, Lauren E. Young, Daniel J. Zabransky, Zhe Zhang, Jane Zorzi, Vered Stearns, and Ben H. Park

387 Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry


Anne Trinh, Kari Trumpi, Felipe De Sousa E Melo, Xin Wang, Joan H. de Jong, Evelyn Fessler, Peter J.K. Kuppen, Marlies S. Reimers, Marloes Swets, Miriam Koopman, Iris D. Nagtegaal, Marnix Jansen, Gerrit K.J. Hooijer, George J.A. Offerhaus, Onno Kranenburg, Cornelis J. Punt, Jan Paul Medema, Florian Markowitz, and Louis Vermeulen

399 PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer

David C. Qian, Xiangjun Xiao, Jinyoung Byun, Arief A. Suriawinata, Stephanie C. Her, Christopher I. Amos, and Richard J. Barth Jr.

Table of Contents

- 407** Estrogen Receptor Binding (¹⁸F-FES PET) and Glycolytic Activity (¹⁸F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER⁺ Breast Cancer
Brenda F. Kurland, Lanell M. Peterson, Jean H. Lee, Erin K. Schubert, Erin R. Currin, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff, and Hannah M. Linden


- 416** Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma
 Francesca Fontana, Xia Ge, Xinming Su, Deep Hathi, Jingyu Xiang, Simone Cenci, Roberto Civitelli, Koorsh I. Shoghi, Walter J. Akers, Andre D'avignon, Katherine N. Weilbaecher, and Monica Shokeen

CANCER THERAPY: PRECLINICAL

- 430** Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Xuguang Zhu, Keisuke Enomoto, Li Zhao, Yuelin J. Zhu, Mark C. Willingham, Paul Meltzer, Jun Qi, and Sheue-yann Cheng
- 441** Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
Alfredo Perales-Puchalt, Nikolaos Svoronos, Melanie R. Rutkowski, Michael J. Allegrezza, Amelia J. Tesone, Kyle K. Payne, Jayamanna Wickramasinghe, Jenny M. Nguyen, Shane W. O'Brien, Kiranmai Gumireddy, Qihong Huang, Mark G. Cadungog, Denise C. Connolly, Julia Tchou, Tyler J. Curiel, and Jose R. Conejo-Garcia
- 454** PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Adrian M. Seifert, Shan Zeng, Jennifer Q. Zhang, Teresa S. Kim, Noah A. Cohen, Michael J. Beckman, Benjamin D. Medina, Joanna H. Maltbaek, Jennifer K. Loo, Megan H. Crawley, Ferdinand Rossi, Peter Besmer, Cristina R. Antonescu, and Ronald P. DeMatteo
- 466** Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Annette Künkele, Agne Taraseviciute, Laura S. Finn, Adam J. Johnson, Carolina Berger, Olivia Finney, Cindy A. Chang, Lisa S. Rolczynski, Christopher Brown, Stephanie Mgebroff, Michael Berger, Julie R. Park, and Michael C. Jensen

- 478** Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer
Hong Liu, Yiyang Xu, Jingyi Xiang, Li Long, Shon Green, Zhiyuan Yang, Bryan Zimdahl, Jingwei Lu, Neal Cheng, Lucas H. Horan, Bin Liu, Su Yan, Pei Wang, Juan Diaz, Lu Jin, Yoko Nakano, Javier F. Morales, Pengbo Zhang, Lian-xing Liu, Binnaz K. Staley, Saul J. Priceman, Christine E. Brown, Stephen J. Forman, Vivien W. Chan, and Cheng Liu

- 489** IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
Elizabeth L. McMichael, Alena Cristina Jaime-Ramirez, Kristan D. Guenterberg, Eric Luedke, Lakhvir S. Atwal, Amanda R. Campbell, Zhiwei Hu, Armika S. Tatum, Sri Vidya Kondadasula, Xiaokui Mo, Susheela Tridandapani, Mark Bloomston, E. Christopher Ellison, Terence M. Williams, Tanios Bekaii-Saab, and William E. Carson III

- 503** Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
 Wei-Jan Wang, Chien-Feng Li, Yu-Yi Chu, Yu-Hui Wang, Tzyh-Chyuan Hour, Chia-Jui Yen, Wen-Chang Chang, and Ju-Ming Wang

- 514** RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Yajing Liu, Monika L. Burness, Rachel Martin-Trevino, Joey Guy, Shoumin Bai, Ramdane Harouaka, Michael D. Brooks, Li Shang, Alex Fox, Tahra K. Luther, April Davis, Trenton L. Baker, Justin Colacino, Shawn G. Clouthier, Zhi-ming Shao, Max S. Wicha, and Suling Liu

- 523** PARP Inhibitor Activity Correlates with *SLFN11* Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell, John T. Poirier, and Charles M. Rudin

- 536** Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Rafael Duran, Sahar Mirpour, Vasily Pekurovsky, Shanmugasundaram Ganapathy-Kanniappan, Cory F. Brayton, Toby C. Cornish, Boris Gorodetski, Juvenal Reyes, Julius Chapiro, Rüdiger E. Scherthaner, Constantine Frangakis, MingDe Lin, Jessica D. Sun, Charles P. Hart, and Jean-François Geschwind

Table of Contents

- 549** ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer
Reba Mustafi, Urszula Dougherty, Devkumar Mustafi, Fatma Ayaloglu-Butun, Michelle Fletcher, Sarbani Adhikari, Farhana Sadiq, Katherine Meckel, Haider I. Haider, Abdurahman Khalil, Joel Pekow, Vani Konda, Loren Joseph, John Hart, Alessandro Fichera, Yan Chun Li, and Marc Bissonnette

BIOLOGY OF HUMAN TUMORS

- 562** Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Roman Reinartz, Shanshan Wang, Sied Kebir, Daniel J. Silver, Anja Wieland, Tong Zheng, Marius Küpper, Laurèl Rauschenbach, Rolf Fimmers, Timothy M. Shepherd, Daniel Trageser, Andreas Till, Niklas Schäfer, Martin Glas, Axel M. Hillmer, Sven Cichon, Amy A. Smith, Torsten Pietsch, Ying Liu, Brent A. Reynolds, Anthony Yachnis, David W. Pincus, Matthias Simon, Oliver Brüstle, Dennis A. Steindler, and Björn Scheffler
- 575** Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway
 Qian Mei, Xiang Li, Kang Zhang, Zhiqiang Wu, Xiaolei Li, Yuanguang Meng, Mingzhou Guo, Guangbin Luo, Xiaobing Fu, and Weidong Han
- 587** Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Naoki Horikawa, Kaoru Abiko, Noriomi Matsumura, Junzo Hamanishi, Tsukasa Baba, Ken Yamaguchi, Yumiko Yoshioka, Masafumi Koshiyama, and Ikuo Konishi

- 600** Alternative Lengthening of Telomeres and Loss of DAXX/ATRAX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Aatur D. Singhi, Ta-Chiang Liu, Justin L. Roncaioli, Dengfeng Cao, Herbert J. Zeh, Amer H. Zureikat, Allan Tsung, J. Wallis Marsh, Kenneth K. Lee, Melissa E. Hogg, Nathan Bahary, Randall E. Brand, Kevin M. McGrath, Adam Slivka, Kristi L. Cressman, Kimberly Fuhrer, and Roderick J. O'Sullivan

CORRECTIONS

- 610** Correction: Genomic *EWSR1* Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
- 611** Correction: The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer

RETRACTION

- 612** Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90




AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a tumor subclone derived from a clinical glioblastoma sample giving rise to multinucleated giant cells *in vitro*. Immunofluorescence depicts expression of β III-tubulin (green) and glial fibrillary acidic protein (GFAP, red). Cellular nuclei were DAPI stained. For details, see the article by Reinartz and colleagues on page 562 of this issue.



Clinical Cancer Research

23 (2)

Clin Cancer Res 2017;23:325-612.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/23/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/2>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.